Crossmark

A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR

Crossref DOI link: https://doi.org/10.1038/cdd.2016.22

Published Online: 2016-04-01

Published Print: 2016-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tosco, A

De Gregorio, F

Esposito, S

De Stefano, D

Sana, I

Ferrari, E

Sepe, A

Salvadori, L

Buonpensiero, P

Di Pasqua, A

Grassia, R

Leone, C A

Guido, S

De Rosa, G

Lusa, S

Bona, G

Stoll, G

Maiuri, M C

Mehta, A

Kroemer, G

Maiuri, L

Raia, V
License Information

Text and Data Mining valid from 2016-04-01

Version of Record valid from 2016-04-01
More Information

Article History

Received: 25 November 2015

Revised: 25 January 2016

Accepted: 27 January 2016

First Online: 1 April 2016

Competing interests

: LM, VR and GK are listed as inventors on a patent application (No. 13/895741) owned by the No-profit Foundation European Institute for Research in Cystic Fibrosis, describing the use of cysteamine for the treatment of CF. The authors declare no conflict of interest.

Updates are available Erratum dated 2016-07-22

Click to view Erratum: https://doi.org/10.1038/cdd.2016.43